Sinotherapeutics Past Earnings Performance
Past criteria checks 1/6
Sinotherapeutics has been growing earnings at an average annual rate of 1.2%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 62.6% per year. Sinotherapeutics's return on equity is 6.4%, and it has net margins of 20.7%.
Key information
1.2%
Earnings growth rate
-1.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 62.6% |
| Return on equity | 6.4% |
| Net Margin | 20.7% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Sinotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 369 | 76 | 45 | 79 |
| 31 Dec 23 | 300 | 61 | 44 | 74 |
| 30 Sep 23 | 274 | 70 | 44 | 68 |
| 30 Jun 23 | 230 | 76 | 41 | 68 |
| 31 Mar 23 | 227 | 80 | 42 | 68 |
| 31 Dec 22 | 248 | 93 | 46 | 76 |
| 30 Sep 22 | 271 | 141 | 43 | 82 |
| 30 Jun 22 | 287 | 138 | 43 | 86 |
| 31 Mar 22 | 301 | 137 | 43 | 96 |
| 31 Dec 21 | 315 | 135 | 46 | 104 |
| 31 Dec 20 | 319 | 123 | 57 | 76 |
| 31 Dec 19 | 139 | 5 | 54 | 51 |
| 31 Dec 18 | 61 | -37 | 33 | 50 |
Quality Earnings: 688247 has a high level of non-cash earnings.
Growing Profit Margin: 688247's current net profit margins (20.7%) are lower than last year (35.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688247 has become profitable over the past 5 years, growing earnings by 1.2% per year.
Accelerating Growth: 688247's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 688247 had negative earnings growth (-5.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.1%).
Return on Equity
High ROE: 688247's Return on Equity (6.4%) is considered low.